Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

ClinicalTrials.gov ID: NCT02575963

Public ClinicalTrials.gov record NCT02575963. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 11, 2026, 9:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia

Study identification

NCT ID: NCT02575963
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Actinium Pharmaceuticals; Industry
Enrollment: 40 participants

Conditions and interventions

Conditions

Interventions

Cytarabine (Phase 1 only) Drug
Furosemide (Phase 1 only) Drug
Lintuzumab-Ac225 Biological
Spironolactone Drug

Drug · Biological

Eligibility (public fields only)

Age range: 60 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2012
Primary completion: Oct 31, 2018
Completion: Apr 30, 2020
Last update posted: Jul 19, 2023

2012 – 2020

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
UCLA Medical Center, Division of Hematology/Oncology	Los Angeles	California	90095	—
University of Kentucky, Markey Cancer Center	Lexington	Kentucky	40536	—
University of Louisville, James Graham Brown Cancer Center	Louisville	Kentucky	40202	—
Ochsner Medical Center, The Gayle and Tom Benson Cancer Center	New Orleans	Louisiana	70121	—
Mayo Clinic	Rochester	Minnesota	55905	—
Weill Medical College of Cornell University	New York	New York	10021	—
Columbia University Medical, Herbert Irving Comprehensive Cancer Center	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Duke Cancer Center	Durham	North Carolina	27705	—
University of Pennsylvania, Perelman Center for Advanced Medicine	Philadelphia	Pennsylvania	19104	—
St. Francis Cancer Center	Greenville	South Carolina	29607	—
Baylor Scott and White Research Institute, Charles A. Sammons Cancer Center	Dallas	Texas	75246	—
Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation	Seattle	Washington	98104	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	—
West Virginia University, Mary Babb Randolph Cancer Center	Morgantown	West Virginia	26506	—
Medical College of Wisconsin Cancer Center	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02575963, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 19, 2023 · Synced May 11, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02575963 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →